PMID- 38039739
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240202
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 253
DP  - 2024 Jan
TI  - ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological 
      and immunohistochemical features by analysis of 276 renal cell carcinoma cases in 
      Turkey.
PG  - 154951
LID - S0344-0338(23)00652-0 [pii]
LID - 10.1016/j.prp.2023.154951 [doi]
AB  - Anaplastic lymphoma kinase (ALK) rearrangement-associated renal cell carcinoma 
      (ALK-RCC) is characterized by ALK fusion at chromosome 2p23. It has recently been 
      included as a recognized entity with the 5th edition of the WHO classification 
      urinary and male genital tumor. However, our knowledge about ALK-RCC is limited 
      due to the small number of reported cases. In our study, we aimed to contribute 
      the histomorphological and immunohistochemical features of ALK-rearranged renal 
      cell carcinoma cases. We reviewed 276 cases diagnosed as RCC in order to detect 
      ALKRCCs.We used immunohistochemistry to screen ALK rearrangement and then 
      confirmed the ALK rearrangement by fluorescence in situ hybridization (FISH) 
      method. ALK was immunohistochemically positive in 8 of 276 cases. ALK 
      rearrangement was detected by FISH in 3 of 8 cases. These cases were previously 
      diagnosed as clear cell renal cell carcinoma (CRCC), papillary renal cell 
      carcinoma (PRCC), and chromophobe renal cell carcinoma (ChRCC). Their 
      histomorphological findings were diverse, and all three cases exhibited different 
      immunohistochemical findings. Survival of these patients ranged between 6 and 24 
      months. ALK immunohistochemical findings were also different in each case as 
      perinuclear, weak cytoplasmic, and membranous.ALK RCCs appear to be very rare 
      tumors with heterogeneous histomorphological and immunohistochemical features. 
      Although immunohistochemistry may be useful to detect ALK positivity, genetic 
      evaluation is required to confirm the diagnosis. With identifying ALK-RCCs, ALK 
      inhibitors, which are currently used in the treatment of lung adenocarcinomas, 
      can be used as a targeted therapy option in ALK-RCCs.
CI  - Copyright (c) 2023 Elsevier GmbH. All rights reserved.
FAU - Dogan, Kutsal
AU  - Dogan K
AD  - Diskapi Yildirim Beyazit Training and Research Hospital Department of Pathology, 
      06100 Ankara, Turkiye. Electronic address: kutsaldogann@gmail.com.
FAU - Onder, Evrim
AU  - Onder E
AD  - Diskapi Yildirim Beyazit Training and Research Hospital Department of Pathology, 
      06100 Ankara, Turkiye.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231120
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Carcinoma, Renal Cell/pathology
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - *Kidney Neoplasms/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Turkey
OTO - NOTNLM
OT  - ALK
OT  - ALK-RCC
OT  - Kidney
OT  - Rearranged RCC
OT  - Renal cell carcinoma
OT  - Uropathology
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/02 00:42
MHDA- 2024/01/24 06:44
CRDT- 2023/12/01 18:09
PHST- 2023/09/11 00:00 [received]
PHST- 2023/11/08 00:00 [revised]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2024/01/24 06:44 [medline]
PHST- 2023/12/02 00:42 [pubmed]
PHST- 2023/12/01 18:09 [entrez]
AID - S0344-0338(23)00652-0 [pii]
AID - 10.1016/j.prp.2023.154951 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2024 Jan;253:154951. doi: 10.1016/j.prp.2023.154951. Epub 2023 
      Nov 20.